Mar 11, 2020 / 02:15PM GMT
Jack Meehan - Barclays Bank PLC, Research Division - VP & Senior Research Analyst
Thank you, and good morning. This is Jack Meehan with the Life Science Tools & Diagnostics team here at Barclays. And pleased to be continuing the Barclays virtual Global Healthcare Conference now with Charles River Chairman and CEO, Jim Foster; as well as Head of Investor Relations, Todd Spencer. I appreciate you guys joining us in the new format. And Jim, just like to turn it over to you for some introductory comments.
James C. Foster - Charles River Laboratories International, Inc. - Chairman, CEO & President
Sure. Thanks. Thanks, Jack. We reported a very strong '19. Sales up 8.5%. Operating margins 19%, up 20 bps. EPS $6.73, up 16%. We were really, really pleased with those results. The guidance for '20 is 7.75% to 8.75% revenue growth and EPS at $7.45 to $7.60.
The RMS segment was up 5 -- a little over 5%, driven principally by China and strength in our GEMS business and IS business. We opened a new facility in South San Francisco, which is an incubated
Charles River Laboratories International Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers